EUVIMEDEUVIMED entdecken
Crossref

Anti‑CGRP monoclonal antibodies in resistant migraine: preliminary real-world effectiveness and clinical predictors of response at two years

E Pons-Fuster, O Lozano-Caballero, S Martín-Balbuena, C Lucas-Ródenas, A Mancebo-González, I De Gorostiza-Frías, C M González-Ponce

International Journal of Clinical Pharmacy · 2024

DOI: 10.1007/s11096-024-01758-2 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Clinical Pharmacy, 2024. Verfasst von E Pons-Fuster und 6 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Pharmacy and Therapeutics Research Group, Servicio de Farmacia Hospitalaria, Virgen de la Arrixaca University Clinical Hospital (HCUVA), Bio…. Hauptthemen laut MEDLINE: Migraine Disorders, Antibodies, Monoclonal, Calcitonin Gene-Related Peptide. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 24 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Migraine DisordersAntibodies, MonoclonalCalcitonin Gene-Related PeptideHumansMaleFemaleRetrospective StudiesAdultMiddle AgedTreatment OutcomeAntibodies, Monoclonal, HumanizedCalcitonin Gene-Related Peptide Receptor AntagonistsPatient Reported Outcome Measures

Stichwörter der Autor:innen

CGRPHeadacheMigraineMonoclonal antibodies

Substanzen

Antibodies, MonoclonalgalcanezumaberenumabfremanezumabCalcitonin Gene-Related PeptideAntibodies, Monoclonal, HumanizedCalcitonin Gene-Related Peptide Receptor Antagonists

Autor:innen und Institutionen

  • Clinical Pharmacy and Therapeutics Research Group, Servicio de Farmacia Hospitalaria, Virgen de la Arrixaca University Clinical Hospital (HCUVA), Biomedical Research Institute of Murcia (IMIB), Ctra. Madrid-Cartagena, s…
  • Headache Unit, Virgen de la Arrixaca University Clinical Hospital (HCUVA), Murcia, Spain.

Zitieren

APA

Pons-Fuster, E., Lozano-Caballero, O., Martín-Balbuena, S., Lucas-Ródenas, C., Mancebo-González, A., De Gorostiza-Frías, I., & González-Ponce, C. M. (2024). Anti‑CGRP monoclonal antibodies in resistant migraine: preliminary real-world effectiveness and clinical predictors of response at two years. International Journal of Clinical Pharmacy. https://doi.org/10.1007/s11096-024-01758-2

Vancouver

Pons-Fuster E, Lozano-Caballero O, Martín-Balbuena S, Lucas-Ródenas C, Mancebo-González A, De Gorostiza-Frías I, et al. Anti‑CGRP monoclonal antibodies in resistant migraine: preliminary real-world effectiveness and clinical predictors of response at two years. International Journal of Clinical Pharmacy. 2024. doi:10.1007/s11096-024-01758-2

BibTeX
@article{PonsFuster2024,
  author = {Pons-Fuster, E and Lozano-Caballero, O and Martín-Balbuena, S and Lucas-Ródenas, C and Mancebo-González, A and De Gorostiza-Frías, I and González-Ponce, C M},
  title = {Anti‑CGRP monoclonal antibodies in resistant migraine: preliminary real-world effectiveness and clinical predictors of response at two years},
  journal = {International Journal of Clinical Pharmacy},
  year = {2024},
  doi = {10.1007/s11096-024-01758-2}
}
Kostenlos starten →